| Landscape scoping & retrieval | Pulls the right trials for the indication/target, uses the search tools systematically, and captures the relevant competitors rather than a partial slice. | Misses major programs, queries haphazardly, or reasons from memory instead of the tool data. |
| Design-delta analysis | Compares trials on the dimensions that matter — phase, line of therapy, control arm, endpoint, enrollment — and surfaces meaningful differences. | Lists trials without comparing them, or compares on irrelevant attributes. |
| Competitive read & leaders | Correctly identifies who leads (most advanced / largest programs) and characterizes the threat level per competitor. | Mis-ranks maturity (e.g. calls a Phase 1 the leader), or ignores the most advanced asset. |
| Whitespace / differentiation | Identifies credible open positions (modality x line combos, endpoints, populations) that follow from the data and would actually differentiate a new entrant. | Invents whitespace contradicted by the trials shown, or gives generic advice not grounded in gaps. |
| Evidence faithfulness | Every claim (NCTs, sponsors, phases, enrollment) traces to tool outputs; no fabricated trials. | Hallucinates trials, sponsors, or numbers, or contradicts the returned data. |